© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
(Reuters) – Revance Therapeutics (NASDAQ:) Inc said on Friday the U.S. Food and Drug Administration had declined to approve its long-acting injectable drug to treat moderate to severe frown lines, sending its shares plunging 29%.
The company said the FDA pointed to “deficiencies” related to the regulator’s inspection of Revance’s manufacturing site.
No other concerns were raised in the agency’s “complete response letter”, the drug developer said.
Revance’s DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc (NYSE:)’s Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018.
In November last year, the U.S. FDA delayed its decision on the drug, as it was unable to conduct required inspection of the company’s manufacturing facility due to COVID-19 travel restrictions. Revance later said it was expecting approval in 2021.
“We are very disappointed by this unanticipated response from the FDA and are seeking further clarity from the agency,” Mark Foley, the chief executive officer of Revance, said in a statement on Friday.
Revance said it plans to request a meeting with the FDA as soon as possible to address the agency’s concerns.
The company’s shares, which closed at $22.71 on Friday, were at $16.20 in extended trade.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment